Adoptive-cell-transfer therapy for the treatment of patients with cancer

Nature Reviews Cancer

Volumn 3, Issue 9, 2003, Pages 666-675

  Dudley, Mark E ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; MELANOCYTE DIFFERENTIATION ANTIGEN; MELANOMA ANTIGEN; OKT 3; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CANCER THERAPY; CELL TRANSFER; CLINICAL ARTICLE; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOBLASTOID CELL; LYMPHOCYTE CULTURE; LYMPHOPROLIFERATIVE DISEASE; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; CLINICAL TRIAL; IMMUNOLOGY; METHODOLOGY; NEOPLASM; SKIN TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; NEOPLASMS; SKIN NEOPLASMS;

EID: 0141688283     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1167     Document Type: Review

References (97)

1. Shastri, N., Schwab, S. & Serwold, T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20, 463-493 (2002).
2. Renkvist, N., Castelli, C., Robbins, P. F. & Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3-15 (2001).
3. Robbins, P. F. et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185-1192 (1996).
4. Jager, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270 (1998).
5. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-352 (1994).
6. Kawakami, Y. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968 (1995).
7. Guidotti, L. G. & Chisari, F. V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65-91 (2001).
8. + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18, 275-308 (2000).
9. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
10. Weber, J. et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97, 186-200 (2003).
11. Wick, M. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238 (1997).
12. Prevost-Blondel, A. et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161, 2187-2194 (1998).
13. Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
14. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
15. + suppressor T cells: more questions than answers. Nature Rev. Immunol. 2, 389-400 (2002).
16. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 183, 5211-5218 (1999).
17. Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3, 999-1005 (2002).
18. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002). This report describes adoptive cell transfer with TILs following non-myeloablative chemotherapy for treatment of patients with melanoma, and represents the first successful use of this combination therapy for the treatment of solid malignancy in patients.
19. Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555 (1998). This paper describes the generation and clinical use of lymphocyte cultures for ACT therapy of patients with metastatic cancer.
20. Overwijk, W. W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277-286 (1998). Demonstration in an animal model that immune manipulation can result in efficacious tumour treatments mediated through unmutated melanocyte-differentiation antigens.
21. Sakai, K., Chang, A. E. & Shu, S. Y. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Cancer Res. 50, 4371-4376 (1990).
22. + T cell reactivity to a model tumor antigen. J. Immunol. 164, 562-565 (2000).
23. Chang, A. E. et al. Clinical observations on adoptive immunotherapy with vaccine-primed T- lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53, 1043-1050 (1993).
24. Peng, L., Shu, S. & Krauss, J. C. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol. 178, 24-32 (1997).
25. Zeh, H. J. 3rd, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., & Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 980-994 (1999).
26. Aruga, A., Shu, S. & Chang, A. E. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41, 317-324 (1995).
27. + tumor-infiltrating lymphocytes. J. Exp. Med. 173, 647-658 (1991).
28. Cameron, R. B., Spiess, P. J. & Rosenberg, S. A. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J. Exp. Med. 171, 249-263 (1990).
29. Cheever, M. A., Greenberg, P. D., Fefer, A. & Gillis, S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med. 155, 968-980 (1982).
30. Chou, T., Bertera, S., Chang, A. E. & Shu, S. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 141, 1775-1781 (1988).
31. Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321 (1986). This seminal paper describes the use of TILs, together with cyclophosphamide conditioning, to treat advanced tumours in mice.
32. Bristol, J. A., Schlom, J. & Abrams, S. I. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Cell Immunol. 194, 78-89 (1999).
33. + cells. J. Exp. Med. (in the press).
34. + suppressor T-cells. Cancer Res. 49, 1649-1654 (1989).
35. Berenson, J. R., Einstein, A. B. Jr & Fefer, A. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J. Immunol. 115, 234-238 (1975).
36. Cheever, M. A., Greenberg, P. D. & Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 125, 711-714 (1980).
37. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063-1074 (1982).
38. Cornoli, P. et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592-2598 (2002).
39. Haque, T. et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436-442 (2002).
40. O'Reilly, R. J. et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev. 157, 195-216 (1997).
41. Lucas, K. G., Small, T. N., Heller, G., Dupont, B. & O'Reilly, R. J. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87, 2594-2603 (1996).
42. Grimm, E. A., Mazumder, A., Zhang, H. Z. & Rosenberg, S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841 (1982).
43. Mule, J. J., Shu, S., Schwarz, S. L. & Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487-1489 (1984).
44. Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
45. Lum, L. G., LeFever, A. V., Treisman, J. S. Garlie, N. K. & Hanson J. P. Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J. Immunother. 24, 408-419 (2001).
46. + T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 16, 2752-2760 (1998).
47. Kim, J. A. et al. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 86, 22-30 (1999).
48. Rosenberg, S. A. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85, 622-632 (1993).
49. Chang, A. E. et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884-890 (2003).
50. To, W. C. et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch. Otolaryngol. Head Neck Surg. 126, 1225-1231 (2000).
51. Plautz, G.E. et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 54, 617-623 (1999).
52. Meijer, S. L. et al. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J. Immunother. 25, 359-372 (2002).
53. Meidenbauer, N. et al. Survival and tumor localization of adoptively transferred melan-a-specific T cells in melanoma patients. J. Immunol. 170, 2161-2169 (2003).
54. Maus, M. V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1 BB. Nature Bictechnol. 20, 143-148 (2002).
55. Thomas, A. K., Maus, M. V., Shalaby, W. S., June, C. H. & Riley, J. L. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin. Immunol. 105, 259-272 (2002).
56. Oelke, M. et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nature Med. 9, 619-624 (2003).
57. Sili, U. et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother. 26, 241-256 (2003).
58. Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995). This influential paper describes the use of CMV-specific cloned lymphocytes for the treatment of bone-marrow-transplant recipients, and their efficacy in prevention of CMV-induced disease.
59. Dudley, M. E. et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373 (2001).
60. Dudley, M. E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251 (2002). The failure of non-myeloablative chemotherapy followed by administration of highly avid T-cell clones for treatment of patients with melanoma is documented.
61. Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168-16173 (2002). An excellent example of the failure of highly avid T-cell clones to induce objective clinical responses in patients with metastatic solid tumours. T-cell function, transport and persistence were monitored.
62. Tan, R. et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93, 1506-1510 (1999).
63. Brodie, S. J. et al. in vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34-41 (1999).
64. + T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J. Immunol. 165, 6047-6055 (2000).
65. Donawho, C. K., Pride, M. W. & Kripke, M. L. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity. Cancer Res. 61, 215-221 (2001).
66. Topalian, S. L. et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839-853 (1988).
67. Kradin, R. L. et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1, 577-580 (1989).
68. Dillman, R. O. et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68, 1-8 (1991).
69. Arienti, F. et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol. Immunother. 36, 315-322 (1993).
70. Figlin, R. A. et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 158, 740-745 (1997).
71. Quattrocchi, K. B. et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45, 141-157 (1999).
72. Valmori, D. et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62, 1743-1750 (2002).
73. Finke, J. H. et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J. Immunother. Emphasis. Tumor Immunol. 15, 91-104 (1994).
74. Hom, S. S., Rosenberg, S. A. & Topalian, S. L. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol. Immunother. 36, 1-8 (1993).
75. Hoshino, T. et al. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int. J. Cancer 70, 631-638 (1997).
76. Nakamura, H., Ishiguro, K., & Mon, T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 62, 2489-2497 (1988).
77. Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A. & Topalian, S. L. Characterization of lymphocytes infiltrating human breast cancer specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12, 1-12 (1992).
78. Itoh, K., Tilden, A. B., & Balch, C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 46, 3011-3017 (1986).
79. Topalian, S. L., Solomon, D., & Rosenberg, S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725 (1989).
80. Yannelli, J. R. et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65, 413-421 (1996).
81. Dudley, M. E., Wunderlich, J, R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342 (2003).
82. Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159-1166 (1994). A comprehensive summary of the clinical experience with TIL for the treatment of patients with melanoma in the absence of non-myeloablative conditioning.
83. Rosenberg, S. A. et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. Med. 323, 570-578 (1990).
84. Maine, G. N. & Mule, J. J. Making room for T cells. J. Clin. Invest. 110, 157-159 (2002).
85. Fry T. J. & Mackall, C. L. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends. Immunol. 22, 564-571 (2001).
86. Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E. & Rosenberg, S. A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19, 3477-3482 (2001).
87. Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644 (2000).
88. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
89. Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982-2987 (1999).
90. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
91. Clay, T. M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J. Immunol. 163, 507-513 (1999).
92. Hwu, P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55, 3369-3373 (1995).
93. Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 4, 225-234 (2003).
94. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260-4266 (2003).
95. Liu, K. & Rosenberg, S. A. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365 (2001).
96. Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
97. Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).